Buprenorphine/naloxone
Suboxone, Zubsolv · ATC code N07BC51
Also known as: Buprenorphin/Naloxon, Buprenorfin/Nalokson, Buprenorfina / naloxone, Buprénorphine / naloxone, Buprenorfina / naloxona, Buprenorphine / Naloxone · Brand names: Suboxone, Zubsolv, Bowielone, Bulnexo, Bupensanduo, Buprenorphin/Naloxon G.L. Pharma, Bupensan Duo
- Key facts
- Active substance
- Buprenorphine/naloxone (INN: buprenorphine / naloxone)
- ATC code
- N07BC51
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Suboxone 2 mg/0.5 mg sublingual tablets / Suboxone 8 mg/2 mg sublingual tablets / Suboxone 16 mg/4 mg sublingual tablets · Suboxone 2 mg/0.5 mg sublingual film / Suboxone 4 mg/1 mg sublingual film / Suboxone 8 mg/2 mg sublingual film · Zubsolv 0.7 mg/0.18 mg sublingual tablets / Zubsolv 1.4 mg/0.36 mg sublingual tablets / Zubsolv 2.9 mg/0.71 mg sublingual tablets
- Marketing authorisation holder
- Indivior Europe Limited, Accord Healthcare S.L.U.
- Information as of
- 2026-10-27
Key facts
Buprenorphine/naloxone combines a partial opioid agonist with an opioid antagonist for substitution treatment of opioid dependence; naloxone is intended to deter intravenous misuse.
What it is used for
- Substitution treatment for opioid drug dependence within a framework of medical, social and psychological treatment
- Adults and adolescents over 15 years of age who have agreed to be treated for addiction
Dosing
- Under supervision of a physician experienced in addiction; induction only when clear signs of withdrawal are evident
- Heroin/short-acting opioids: first dose not less than 6 hours after last use; methadone: reduce to max 30 mg/day first, first dose not less than 24 hours after last methadone
- Suboxone: starting dose 4 mg/1 mg, repeatable up to 12 mg/3 mg on day 1; maximum single daily dose 24 mg buprenorphine
- Suboxone: after stabilisation, dosing every other day at twice the daily dose or 3 times a week may be possible
- Zubsolv: starting dose 1.4 mg/0.36 mg or 2.9 mg/0.71 mg a day; not interchangeable with other buprenorphine products (different bioavailability)
- Sublingual use; further schemes in the full text
Contraindications
- Hypersensitivity to the active substances or any excipient
- Severe respiratory insufficiency; severe hepatic impairment
- Acute alcoholism or delirium tremens
- Concomitant opioid antagonists (naltrexone, nalmefene) for alcohol or opioid dependence
Important warnings
- Misuse, abuse and diversion: risks include overdose, infections, respiratory depression and hepatic injury
- Underdosing may lead to self-medication with opioids, alcohol or benzodiazepines
- Buprenorphine may precipitate withdrawal in methadone-dependent patients
- Precautions against misuse, e.g. avoiding multiple refills early in treatment and regular follow-up
Side effects
- Most common: constipation and withdrawal-type symptoms such as insomnia, headache, nausea, hyperhidrosis and pain
- Considered serious: seizure, vomiting, diarrhoea and elevated liver function tests
- Film: oral hypoesthesia (sublingual) or oral mucosal erythema (buccal)
Interactions
- Not to be taken with alcohol or alcohol-containing medicines (increased sedation)
- Benzodiazepines and other sedatives: increased risk of sedation, respiratory depression, coma and death; dose and duration limited
Pregnancy and breastfeeding
- No or limited data in pregnancy; towards the end of pregnancy, respiratory depression in the newborn is possible
- Long-term use during the last three months may cause a neonatal withdrawal syndrome
Summary of the official product information, written with AI on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
Source: European Medicines Agency (EMA), product information
Germany
- BowieloneEthypharm · 1 register entry
- BulnexoAlkaloid-Int D.O.O. · 1 register entry
- BupensanduoG.L. Pharma Gmbh · 1 register entry
- Buprenorphin/Naloxon G.L. PharmaG.L. Pharma Gmbh · 1 register entry
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Austria
- Bupensan DuoG.L. Pharma Gmbh · 1 register entry
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Turkey
- SuboxoneLİBA LABORATUARLARI A.Ş. · 4 register entries
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 26 more European countries
- Belgium
- Libroxar
- Bulgaria
- Булнексо
- Croatia
- Bulnexo, Bunalict, Bupensanduo
- Cyprus
- Libroxar
- Czechia
- Bupensanduo, Libroxar
- Denmark
- Bunalict, Buprenorphin/Naloxon G.L. Pharma, Buprenorphin/Naloxon Viatris
- Estonia
- Bupensanduo
- Finland
- Bunalict, Buprenorphine/Naloxone G.L. Pharma, Buprenorphine/Naloxone Viatris
- France
- Buprenorphine / Naloxone Viatris, Buprenorphine/Naloxone Arrow, Buprenorphine/Naloxone G.L. Pharma, Buprenorphine/Naloxone Viatris
- Greece
- Libroxar
- Hungary
- Bulnexo
- Iceland
- Suboxone, Zubsolv
- Ireland
- Bulexin, Buprenorphine/Naloxone Pinewood
- Italy
- Bunamol, Buprenorfina E Naloxone Ethypharm, Buprenorfina E Naloxone G.L. Pharma, Buprenorfina E Naloxone Mylan Pharma
- Latvia
- Bupensanduo
- Liechtenstein
- Suboxone, Zubsolv
- Lithuania
- Bupensanduo
- Luxembourg
- Libroxar
- Malta
- Libroxar
- Netherlands
- Bunalict, Buprenorfine/Naloxon Viatris, Buprenorphine Hydrochloride/Naloxon Hydrochloride Dihydrate Aurobindo, Libroxar
- Norway
- Bunalict, Suboxone, Zubsolv
- Portugal
- Buprenorfina + Naloxona Generis
- Slovakia
- Bupensanduo
- Slovenia
- Bulnexo
- Spain
- Buprenorfina/Naloxona Aurovitas
- Sweden
- Bunalict, Buprenorphine/Naloxone G.L. Pharma, Buprenorphine/Naloxone Viatris
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Suboxone – EPAR, Product Information. 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/suboxone-epar-product-information_en.pdf
- European Medicines Agency. Zubsolv – EPAR, Product Information. 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/zubsolv-epar-product-information_en.pdf
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.